SLDB•benzinga•
Solid Biosciences Announces Clinical Pipeline Updates: SGT-003 Tolerated In Duchenne Trial; SGT-212 FA Study For 2H 2025; SGT-501 IND Submission By H1 2025; $148.9M Cash Funding Through 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 15, 2025 by benzinga